

Original Full Length Article

High abundance of CD271⁺ multipotential stromal cells (MSCs) in intramedullary cavities of long bonesGeorge Cox^{a,1}, Sally A. Boxall^{b,1}, Peter V. Giannoudis^a, Conor T. Buckley^c, Tarek Roshdy^a, Sarah M. Churchman^b, Dennis McGonagle^b, Elena Jones^{b,*}^a Academic Department of Trauma & Orthopaedics, School of Medicine, University of Leeds, UK^b Academic Unit of the Musculoskeletal Diseases, Leeds NIHR Biomedical Research Unit, University of Leeds, UK^c Trinity Centre for Bioengineering, School of Engineering, Trinity College Dublin, Ireland

ARTICLE INFO

Article history:

Received 5 May 2011

Revised 29 June 2011

Accepted 14 July 2011

Available online 23 July 2011

Edited by: Clifford Rosen

Keywords:

Multipotential stromal cells

Mesenchymal stem cells

Long bone

Bone marrow

Intramedullary cavity

Bone regeneration

ABSTRACT

Aspiration of iliac crest bone marrow (ICBM) remains the most frequent technique used in harvesting multipotential stromal cells (MSCs) for bone regeneration. Although this tissue type is easily accessed by a surgeon, it has a low frequency of MSCs, which is significant given the high cell numbers required for bone regeneration strategies. Lipoaspirates possess higher MSC frequencies, albeit cells with a differentiation profile less suited to orthopaedic interventions. Intra-medullary cavities of long bones have previously been shown to harbour MSCs in animals, however evaluation of their frequency, differentiation capacity and phenotype in humans had not previously been performed.


Long bone fatty bone marrow (LBFMB) was collected prior to harvesting bone graft. Basic cellular compositions of donor-matched LBFMB and ICBM aspirates, including the numbers of CD34⁺ hematopoietic stem cells and CD31⁺ endothelial cells, were similar. MSCs were enumerated using colony-forming-unit-fibroblast assays and flow cytometry for the presence of a resident LBFMB CD45^{−/low} CD271⁺ MSC population and revealed a trend for higher MSC numbers (average 5 fold, n = 6) per millilitre of LBFMB compared to donor-matched ICBM. Functional characteristics of resident MSCs, including their growth rates, differentiation potentials and surface phenotypes (CD73⁺CD105⁺CD90⁺) before and after culture-amplification, were similar. Enhanced numbers of MSCs could be recovered following brief enzymatic treatment of solid fragments of LBFMB.

Our findings therefore reveal that the intramedullary cavity of the human femur is a depot of MSCs, which, although closely associated with fat, have a differentiation profile equivalent to ICBM. This anatomical site is frequently accessed by the orthopaedic/trauma surgeon and aspiration of the intramedullary cavity represents a 'low-tech' method of harvesting potentially large numbers of MSCs for regenerative therapies and research.

This article is part of a Special Issue entitled: *Interactions Between Bone, Adipose Tissue and Metabolism*.

© 2011 Elsevier Inc. Open access under [CC BY license](http://creativecommons.org/licenses/by/3.0/).

Similar papers at core.ac.uk

brought to you by  CORE

provided by Elsevier - Publisher Connector

from which multipotential stromal cells (MSCs), also termed mesenchymal stem cells, were isolated [1]. This anatomical site has become the most frequently accessed in harvesting MSCs for bone tissue engineering and is generally accepted as the 'gold-standard'. Whilst this source is readily accessible and has good handling properties it has a low frequency of MSCs (0.001–0.01%) [1]. This is of significance as many regenerative medicine uses of MSCs including putative bone repair

that have reduced differentiation capacity [5] and impaired cell function including gradual accumulation of senescence-related markers [6,7] and increased potential for transformation [8]. This process is also time-inefficient, expensive and requires industrial-scale good-manufacturing practice (GMP)-compatible cell expansion facilities and a two-stage surgery for tissue procurement and implantation [9].

Due to these factors there is a need to find alternative MSC sources where there is a potentially larger yield of cells. Initial techniques involved the development of devices to concentrate MSCs from large volumes of ICBM aspirate by centrifugation [10]— and such devices are available in the clinic. The implantation of 50,000 uncultured MSCs/CFU-Fs by concentrating up to 300 ml of ICBMA has shown an improvement of fracture healing in one study [10]. However, it is not always possible to

* Corresponding author at: Academic Unit of the Musculoskeletal Diseases, Leeds Institute of Molecular Medicine, Clinical Sciences Building, St James's University Hospital, Leeds LS9 7TF, United Kingdom. Fax: +44 113 3438502.

E-mail address: msje@leeds.ac.uk (E. Jones).

¹ These authors contributed equally to this work.

obtain such large amounts of ICBMA. The enzymatic digestion of adipose-rich connective tissues such as fat has been proposed as an alternative strategy, with authors reporting the liberation of 500-fold more MSCs per gram of tissue when compared with ICBMA [11]. Lipoaspiration however cannot be performed for every orthopedic patient and the “quality” of lipoaspirate-derived MSCs for bone repair applications remains debatable [12–17].

Multipotential stromal cells have previously been shown to be present in the intramedullary cavity of long bones in humans [18]. However, this has been largely ignored as a source of MSCs for bone regeneration. In contrast, the harvesting of long-bone BM has been practiced on rat [19], mouse [20], rabbit [21–23] and pig [24,25] and is probably the most prevalent research method of isolating MSCs from animals. Analogous to other adipose-rich tissues, it may be hypothesized that the intra-medullary (IM) contents of long bones contain large numbers of MSCs. Unlike peripheral fat tissues, the MSCs are present in a bone related micro-environment and may potentially exhibit good intrinsic osteogenic capabilities. This is supported by early pioneering findings documenting a strong *in vivo* osteogenic capacity of adipogenic marrow cells [23].

This study explored the aspirated contents from the IM cavities of long bones, which are frequently accessed by the trauma/orthopaedic surgeon, as a source of MSCs in comparison to the ‘gold standard’ iliac crest aspirated source. We used colony-forming fibroblast (CFU-F) assay [26] and flow cytometry for CD45^{−/low}CD271⁺ fraction [27–29] to enumerate MSCs and compared their frequency with donor-matched ICBM aspirates. We also used functional *in vitro* assays for MSC expansion and differentiation, to demonstrate that MSCs from IM cavities of long bones were equal or superior to their ICBMA counterparts. These findings should permit the development of novel one-step MSC harvesting procedures for bone repair augmentation in fracture patients.

Materials and methods

Subjects and specimen collection

Approval for these studies was obtained from the Leeds Teaching Hospital NHS trust ethics committee, with all patients providing informed consent. For the purpose of this research, iliac crest bone marrow aspirate (ICBMA) was obtained from 11 acute trauma patients, 11 patients with post-traumatic disorders, 15 patients with long bone (tibia/femur) non-union fractures and 6 healthy controls (Table 1). Samples were harvested from patients during operation; ICBMA (10 ml) was aspirated from the anterior iliac crest, using an 11-gauge, bevel-tipped trocar (Stryker, Kalamazoo, Michigan, US) and 10 ml syringe (BD Biosciences, Oxford, UK). Donor-matched ICBMA and LBFMB material was collected from 8 patients with non-union fractures (median age 35 years, range 19–65).

The LBFMB contents were aspirated via the greater trochanter, which was opened surgically, prior to the harvest of bone graft using the

reamer-irrigator-aspirator (RIA) (Synthes, Westchester, Pennsylvania, USA) for the grafting of non-unions [30]. Following the operative opening of this cavity, via the greater trochanter, suction tubing and 50 ml bladder syringe was used to collect the sample. In some patients with fracture non-union 10 ml of peripheral blood (PB) was also collected (n = 5). Samples were transferred immediately into EDTA containing vacutainers (BD Biosciences) and transported to the laboratory.

Specimen processing

Samples were processed under aseptic conditions and sample volumes in millilitres were recorded. The average sample volume for long bone fatty bone marrow aspirate was 12 ml (range 11–17 ml); ICBM aspirate volume was always 10 ml. A manual nucleated cell (NC) count was performed on every sample following red cell lysis in 4% acetic acid (Sigma, Gillingham, UK). In some experiments (n = 4), the aspirated IM contents were left at room temperature for 1 h, during which the fatty contents congealed leading to the formation of ‘solid’ and ‘liquid’ phases. To physically separate these phases, samples were passed through a 70 µm cell strainer (BD Biosciences). The resulting solid phase was digested using collagenase (Stem Cell Technologies, Grenoble, France) at 1:1 ratio w/v (final concentration = 0.125%), for 60 min at 37 °C. Subsequently all fractions were used for CFU-F assay or initiation of *in vitro* MSC cultures. In some experiments (n = 7), mononuclear cells (MNCs) were isolated using Lymphoprep (Axis-shield, Huntingdon, UK) and counted, as described previously [27].

CFU-F assay and MSC expansion

CFU-F assay was performed as previously described [26] with minor modifications. Briefly, 100 µl or 200 µl of each sample (200 µl or 400 µl of the matched FBM-solid fraction to account for dilution with collagenase) was directly plated into a 10 cm diameter petri-dish (Corning Life Sciences, Amsterdam, Holland) with 15 ml of non-haematopoietic media (Miltenyi Biotec, Bisley, UK) in duplicate. Cells were allowed 48 h to adhere, after which red blood cells and other non-adherent cells were removed with two washes of phosphate buffered saline (PBS) (Invitrogen, Paisley, UK). Adherent cells were cultured (37 °C, 5% CO₂) with half-media changes performed twice weekly. PB MNCs were seeded at 5 × 10⁶ cell/dish and cultured similarly [31]. Crystal violet staining was performed on the fourteenth day, as previously described [32] before scoring blindly.

Expansion was performed to produce sufficient cells to undertake trilineage differentiation and cell surface phenotyping in all fractions as previously described [32]. Cells were expanded until 80% confluency was attained (denoted as passage 0/P0), after which cells were trypsinised and passaged up to P3 [32,33]. Population

Table 1
Characteristics of patients participating in this study.

Patient group	Diagnosis	Procedure	Time of procedure after initial injury, median (range)	Age, years, median (range)	CFU-F/ml of ICBMA, median (range)
Acute trauma (n = 11)	Fracture of pelvis (n = 10) Fracture of tibial plateau (n = 1)	Open reduction and internal fixation (n = 11)	3 days (0–10 days)	42 (21–72)	48 (11–1500)
Post-traumatic disorders (n = 11)	Post traumatic sacroiliac joint instability (n = 2) Other (n = 9) ^a	Injection (n = 2) Removal of metal (n = 2) Other ^b (n = 7)	3 months (1–48 months)	33 (18–67)	90 (6–1445)
Established atrophic non-union (n = 15)	Fracture non-union (femur, n = 9, tibia, n = 6)	Reamer-Irrigator aspiration	18 months (6–72 months)	39 (19–65)	139 (8–2110)
Normal controls (n = 6)	NA	ICBM harvest for allogeneic transplant	NA	35.5 (19–58)	148 (48–1943)

NA — not applicable.

^a Include post traumatic heterotrophic bone formation, infection, meniscal injury, and coccydynia.

^b Include excision, debridement, and arthroscopy.

doublings (PDs) were calculated according to the following formula:
 $PDs = \log^2(N \text{ total cells} / \text{Total CFU-F on day 0})$ [33].

Tri-lineage differentiation

Passage-3 MSCs ($n = 4$ donors) were induced towards osteogenesis, chondrogenesis and adipogenesis according to standard protocols [1,32]. For osteogenesis, cells were seeded at a density of 3×10^4 /well in 3 cm diameter wells (Corning Life Sciences) and cultured in low glucose DMEM with 10% FCS, supplemented with standard antibiotic mixture (100 U/ml penicillin and 100 µg/ml streptomycin) (all from Invitrogen), 100 nM dexamethasone, 10 mM β-glycerolphosphate and 0.05 mM ascorbic acid (all from Sigma), with twice weekly half-media changes. Alkaline phosphatase activity was assessed on day 14 post-induction, as previously described [32]. For adipogenesis, cells were seeded in 12-well plates at 1×10^5 cells/well and cultured in low glucose DMEM with 10% FCS, antibiotics, 10% horse serum (Stem Cell Technologies), 0.5 mM isobutylmethylxanthine, 60 µM indomethacin and 0.5 µM hydrocortisone (all from Sigma). Cultures were stained on day 14 post-induction with Oil-Red-O, as previously described [27,32].

A 3D pellet culture model was used to induce chondrogenesis as previously described [32] with minor modifications. Briefly, pellets were formed in 1.5 ml micro-centrifuge tubes by centrifugation (650 g, 5 min) of 2.5×10^5 cells suspended in 1 ml of serum-free medium consisting of high glucose DMEM (Invitrogen), antibiotics, 40 µg/ml L-proline, 1.5 mg/ml BSA, 4.7 µg/ml linoleic acid, $1 \times$ insulin–transferrin–selenium, 50 µg/ml L-ascorbic acid-2-phosphate, 100 nM dexamethasone (all from Sigma) and 10 ng/ml TGF-β3 (R&D Systems, Abingdon, UK). Full media changes were performed twice weekly and biochemical assessment performed at 21 days as previously described [34] with minor modifications. Briefly, pellets were digested for 18 h at 60 °C, with a papain digestion solution containing 100 mM Sodium Phosphate Buffer supplemented with 5 mM Na₂EDTA, 10 mM L-cysteine and 0.125 mg/ml papain (all from Sigma). DNA content was assessed using a Quant-iT™ PicoGreen® dsDNA Reagent Kit (Invitrogen) and produced glycosaminoglycan (GAG) was measured using a Blyscan™ kit (Biocolor Life Sciences, Co Antrim, Ireland).

Surface phenotype of culture expanded MSCs

Passage-3 MSCs ($n = 3$ donors) were trypsinised and re-suspended at 10^7 cells per ml in FACS buffer (PBS + 0.5% BSA) before surface staining with CD45 (Leukocyte Common Antigen)-PE-Cy7, CD34 (gp105–120)-PerCp (BD Biosciences), CD271 (Nerve growth factor receptor)-APC (Miltenyi Biotec), and a pair of FITC- and PE-labelled antibodies, including: CD31 (PECAM-1)-FITC (Serotec, Kidlington, UK), CD33 (gp67)-FITC, CD61 (Integrin β3)-FITC, CD73 (5' Ecto-nucleotidase)-PE, CD19-PE (BD Biosciences), CD105 (Endoglin)-PE and CD90 (Thy1)-PE (Serotec). All antibodies were used at the manufacturers' recommended concentrations with matched isotype controls (from Serotec). Dead/dying cells were excluded from the analysis using DAPI (Sigma) and were normally less than 5%. Data were analysed on an LSRII flow cytometer equipped with DIVA software (BD Biosciences).

MSC enumeration

The phenotypic identification of the 'ex-vivo MSC' using the CD45^{−/low}CD271⁺ phenotype was first described by our group using ICBMA [27,28,35] and has since been independently validated by others [29,36,37]. MSC enumeration was performed by staining the aspirated MNC fraction with CD45-FITC (Dako UK Ltd, Ely, UK), CD271-PE (Miltenyi Biotec) and 7-AAD, as previously described [28]. A minimum of 5×10^5 events were acquired and analysed using an LSRII flow cytometer to establish the percentage of CD45^{−/low}CD271⁺ cells. The frequency of CD45^{−/low}CD271⁺ per ml of sample was then calculated based on the

following formula: $CD45^{-/low}CD271^{+} \text{ cells/ml} = \% CD45^{-/low}CD271^{+} \text{ cells} \times \text{MNCs/ml}$.

Extended phenotypic analysis of 'ex-vivo MSC' using 6-colour flow cytometry

Bone marrow MNCs were isolated using Lymphoprep and cells were then re-suspended at 1×10^7 cells/ml in FACS buffer. Antibodies were added at the manufacturers' recommended concentrations and the cells were incubated for 20 min. Antibodies used were: CD45-PECy7, CD73-PE, CD34-PerCp, CD19-PE, CD33-FITC, CD61-FITC (BD Biosciences), CD90-PE, CD105-PE, CD31-FITC (Serotec) and CD271-APC (Miltenyi Biotec). The cells were washed and re-suspended in FACS buffer containing 100 ng/ml DAPI before analysing on an LSRII flow cytometer. Dead cells were excluded from the analysis using DAPI (usually <5%) before gating on the CD45^{−/low}CD271⁺ cell population and assessing the expression of all other markers.

Statistics

Statistical analysis and graphing were performed using GraphPad Prism version 4 for Windows (San Diego, California, USA). Gaussian distribution could not be assumed given the number of samples and differences between donor-matched ICBMA and LBFMB groups were tested using Wilcoxon signed ranks test. The differences in the MSC content between different patient groups were analysed using Mann–Whitney test. Significance was assumed when $p < 0.05$.

Results

Basic cellular characterisation of ICBM and LBFMB aspirates

A standard CFU-F assay was first performed to measure the MSC content of ICBM aspirates in three groups of orthopaedic patients and healthy controls (Table 1). Consistent with previously reported findings [10], high donor-to-donor variation was observed, potentially due to factors related to donor age [38] or a variable degree of dilution of ICBM sample with blood during the aspiration procedure [39]. No significant differences in CFU-F abundance in ICBMA were found between all three groups of orthopaedic patients and healthy controls (Table 1). A flow cytometry-based 'instant' enumeration of MSCs was additionally performed based on their CD45^{−/low}CD271⁺ phenotype. Consistent with our previous data [28], direct positive correlation was observed between the numbers of CFU-Fs and CD45^{−/low}CD271⁺ cells per ml of ICBMA ($r = 0.700$, $p = 0.013$, $n = 13$). These data confirmed a possibility of using flow cytometry for enumerating MSCs in other marrow sources, including LBFMB aspirates.

The analysis of different hematopoietic and non-hematopoietic cell types in ICBM and LBFMB aspirates was first performed to compare their basic cellular composition (Fig. 1). The cellularity (both as total NC and MNC counts) of LBFMB aspirates was similar to donor-matched ICBM aspirates (Figs. 1A and B). The majority of cells in both tissues were CD45⁺ leukocytes, including CD19⁺ B-cells, CD33⁺ myeloid cells and CD61⁺ megakaryocytes/platelets (Figs. 1C and D). Similar to other cell types, the numbers of cells with pro-healing capabilities: CD34⁺ hematopoietic progenitor cells and CD31⁺ endothelial/angiogenic cells [40] were not statistically different between the two sources (Figs. 1C and D).

Resident MSCs were measured using CFU-F assay and flow cytometry for the CD45^{−/low}CD271⁺ cell population (Figs. 1E–I). The frequency of CD45^{low}CD271⁺ cells was higher in LBFMB aspirate (Fig. 1E). In correspondence, LBFMB aspirate contained higher numbers of CFU-Fs compared to ICBMA (median values 293 and 115 CFU-F/ml, respectively), however differences narrowly failed to reach statistical significance ($p = 0.0515$, Fig. 1F). CFU-F dishes from a representative donor are shown on Fig. 1G. A similar trend for the MSC increase in LBFMBMA was observed




Fig. 1. Cellular characterisation of ICBM and LBFMB aspirates. A – Total nucleated cell count in ICBMA (white bar) and LBFMB (grey bar, $n=9$) after red cell lysis. B – Mononuclear cell count in ICBMA (white bar) and LBFMB (grey bar, $n=7$) after MNC isolation using a density gradient. C – Proportions of leukocytes (CD45), B cells (CD19), myeloid cells (CD33) and endothelial cells (CD31) in MNC fraction. D – Proportions of megakaryocytic (CD61) and hematopoietic progenitor (CD34) cells. E – Proportions of $CD45^{-low}CD271^{+}$ MSCs. F – Total numbers of CFU-Fs per ml. G – CFU-F dishes from a representative donor showing increased numbers of colonies in LBFMB. I – Total numbers of $CD45^{-low}CD271^{+}$ cells per ml. H – Flow cytometry plots from a representative donor showing increased numbers of $CD45^{-low}CD271^{+}$ cells in LBFMB. Donor-matched samples are used in all experiments, error bars represent SDs.

following the measurements of $CD45^{-low}CD271^{+}$ cells/ml (Fig. 1H). Flow cytometry data from a representative donor are shown in Fig. 1I. It is noteworthy, that no CFU-Fs/MSCs were found in PB of patients with fracture non-unions ($n=5$). Based on these findings it is evident that LBFMB aspirates were not inferior to ICBMA in terms of the proportions of regenerative cells and MSCs per sample volume.

Extended phenotypic characterisation of uncultured MSCs in LBFMB aspirates

Although MSCs were found in similar proportions in LBFMB and ICBM aspirates, their functional and phenotypic characteristics could be altered in fatty environments. An extended phenotypic analysis of $CD45^{-low}CD271^{+}$ 'ex vivo' MSCs in LBFMB and ICBM aspirates was undertaken to identify any potential differences in surface receptor expression. The gating strategy for this analysis is shown in Fig. 2A. CD73 (5' Ecto-nucleotidase) is a broadly-accepted MSC marker [1,39] and it was expressed at similar levels on $CD45^{-low}CD271^{+}$ 'ex vivo' MSCs from both sources ($\sim 91\%$, $n=3$) (Fig. 2B). The MSC markers CD105 (Endoglin) and CD90 (Thy1) were expressed at similar levels in LBFMB and ICBM aspirates (Fig. 2B) whereas CD31 (PECAM-1), an endothelial cell marker, was negative. Finally, we investigated the expression of CD34 molecule on MSCs from ICBMA and LBFMB. This was based on recently-published evidence of CD34 being present on MSCs from lipospiates [41]. Consistent with our previous findings relating to ICBMA [27], CD34 was absent on $CD45^{-low}CD271^{+}$ MSCs from both bone sources (Fig. 2B). Overall, MSC marker expression levels were similar in LBFMB and ICBM aspirates and representative marker histograms are shown on Fig. 2C. Therefore, based on the expression of 5 selected surface markers, $CD45^{-low}CD271^{+}$ cells from LBFMB aspirates had classical 'ex vivo' BM MSC phenotype, similar to ICBMA and different from lipospiates.




Fig. 2. Phenotypic characterisation of 'ex vivo' MSCs in ICBM and LBFMB aspirates. A – Gating strategy: MNCs were gated on SSC/FSC to exclude cell debris and DAPI exclusion was used to remove non-specific fluorescence by dying/dead cells. The $CD45^{-low}CD271^{+}$ cells were then gated as the population of interest and expression of other markers (CD73 and CD31 shown as examples) was characterised within this population. B – The expression of classic MSC markers CD73, CD90 and CD105 and the lack of CD34, CD31, CD61, CD19 and CD33 on gated $CD45^{-low}CD271^{+}$ cells from ICBMA (white) and LBFMB (grey) ($n=3$ matched donors, error bars represent SDs). C – Histograms showing the expression of markers on gated $CD45^{-low}CD271^{+}$ cells from ICBMA (white) and LBFMB (grey) from one representative donor. Dotted lines show isotype control.

Phenotypic characterisation of MSC cultures generated from LBFMB and ICBM aspirates

Although MSC numbers and phenotypes were similar in ICBM and LBFMB aspirates, functional differences in MSCs could exist, due to their anatomical locations. We next compared growth and phenotypic characteristics of MSC cultures obtained from LBFMB and ICBM aspirates (Fig. 3).

No statistically significant differences were found in the growth rates, measured as days/PD up to P3, of ICBMA and LBFMB derived MSC cultures (median values of 2.36 and 2.44, respectively, Fig. 3A). Early-passage cultures (P3) from both sources had indistinguishable morphology (Fig. 3B) and similar phenotypes, using an extended panel of 10 surface markers (Fig. 3C). The majority of cultured cells expressed MSC markers CD73, CD90 and CD105 and were negative for hematopoietic lineage cell markers as well as CD31 and CD34. Representative histograms are shown on Fig. 3D. Altogether these data showed that LBFMB aspirates were similar to donor-matched ICBM aspirates in terms of growth and phenotypic characteristics of resident MSCs.

Differentiation potentials of MSCs derived from LBFMB and ICBM aspirates

To investigate tripotentiality, P3-MSC cultures derived from ICBM and LBFMB aspirates were placed in osteo-, adipo- and chondrogenic differentiation conditions ($n = 4$ donors) (Fig. 4). All cultures exposed to osteogenic induction conditions for 14 days contained polygonal




Fig. 3. Phenotypic characterisation of MSC cultures generated from ICBM and LBFMB aspirates. A – MSC growth rates and B – morphological appearance ($\times 40$ magnification). C – Classic MSC phenotype of cultures generated from ICBMA (white) and LBFMB (grey) ($n = 3$ matched donors, error bars represent SDs). D – Histograms showing the expression of markers on MSCs cultured from ICBMA (white) and LBFMB (grey) from one representative donor. Dotted lines show isotype control.




Fig. 4. Differentiation potentials of MSCs derived from LBFMB aspirates. Day 14 osteogenesis: A – Unstained and B – stained for alkaline phosphatase (microphotographs $\times 40$ magnification). Day 21-adipogenesis: C – Unstained and D – stained for Oil Red (microphotographs $\times 100$ magnification). Day 21 – chondrogenesis: E – Amount of glycosaminoglycan (GAG) produced by the digested pellet cultures. F – Amount of DNA present in each pellet culture. G – To account for the varying cell growth within the pellet cultures the amount of glycosaminoglycan (GAG) produced per μg of DNA in the pellet was calculated.

cells consistent with osteoblastic progression (Fig. 4A). No obvious pattern of differences between ICBM and LBFMB aspirates was documented in the proportions of alkaline-phosphatase positive cells (Fig. 4B). Similar data were obtained for adipogenesis: all MSCs were able to produce Oil-Red positive mature adipocytes, with no apparent gross differences between the samples (Figs. 4C and D). Chondrogenesis was performed using a classical pellet culture [27] and measured as accumulation of cartilage-specific proteoglycans per cell [34]. Similarly to osteo- and adipogenesis, no significant differences between ICBM- and LBFMB-derived pellets were found (Figs. 4E–G).

We next investigated whether any observed donor-to-donor differences could be attributed to the “in vitro age” of tested cultures (measured as total PDs at P3, i.e. prior to differentiation). On average, MSCs from ICBM aspirates and LBFMB aspirates have both undergone 16PDs, with no apparent correlations being found between the “in vitro age” and functional outcomes for individual cultures. Overall, all these functional data showed that LBFMB MSCs were osteogenic and chondrogenic at the levels comparable, and often superior, to ICBM MSCs, making them suitable for therapeutic bone repair applications.

Enhanced release of MSCs from LBFMB aspirates using an enzymatic digestion technique

Following 1-hour storage at RT, fatty components of LBFMB aspirates tend to congeal, resulting in the formation of fatty solid aggregates. To extract increased numbers of MSCs from this material, the solid aggregates from LBFMB aspirates were exposed to a brief enzymatic digestion (Fig. 5).

Although a trend for higher numbers of CFU-F/ml was found in the solid phase (Figs. 5A and B), the differences were not statistically different between liquid and solid phases. Similar findings were observed for percentages of CD45^{low}CD271⁺ cells (Figs. 5C and D). Fatty solid aggregates contributed to ~23% of total sample volume (Fig. 5E) and contained the equivalent of ~30% of the total sample's CFU-Fs (Fig. 5F). At room temperature these MSCs are “trapped” in the solid fatty aggregate, but were easily released by a brief enzymatic digestion. Alternatively, samples could be kept at body temperature




Fig. 5. Enzymatic release of MSCs from LBFMB aspirates. A – Total numbers of CFU-Fs per ml. B – CFU-F dishes from a representative donor showing increased numbers of colonies in the solid fraction. C – Percentages of CD45^{low}CD271⁺ cells in MNC fraction. D – Flow cytometry plots from a representative donor showing increased numbers of CD45^{low}CD271⁺ cells in the solid fraction. Relative volumes (E) and relative CFU-F yields (F) in liquid and solid fractions (n = 4 donors, error bars represent SDs).

(or at 37 °C in the laboratory) to avoid the loss of MSCs due to solidification of fatty components.

Discussion

The conversion of red marrow to yellow marrow is a physiologically dynamic process that starts in infancy at the terminal phalanges and progresses in a centripetal direction [42], so that by adulthood the diaphyses of long-bones are almost entirely populated by yellow, fatty bone marrow [43]. MSCs are commonly harvested from long-bones in rat [19], mouse [20], rabbit [21,23] and porcine [24,25] models. In contrast to human subjects, the description of a yellow fatty appearance of the long bone marrow in these reports is rarely mentioned, which may be partly due to the fact that the majority of animal models are sacrificed at a juvenile stage – possibly prior to red marrow conversion. The aim of this study was to comprehensively assess human LBFMB as a source of MSCs for bone repair applications and to compare it with ICBM aspirate.

Using donor-matched samples, we have found that LBFMB was non-inferior to ICBMA in terms of its cellularity, basic cellular composition and the proportions of MSCs. In fact, LBFMB had higher proportions of CFU-Fs compared to ICBMA (2.5-fold). These differences narrowly failed to reach statistical significance but in a larger scale study they may do so. Despite the fatty environment within LBFMB cavity, LBFMB-derived MSCs possessed the classical MSC phenotype, before and after culture, arguing for good preservation of their undifferentiated status. Furthermore, LBFMB-derived MSCs had similar growth characteristics and multipotential properties as their ICBMA counterparts. This is of interest as MSCs from other adipogenic sources have often been shown to be inferior to ICBMA in forming bone [12,13] and this may be related to the intra-osseous location of MSCs in long-bone cavities.

Numerous literature reports describing the presence of CFU-F/MSCs in connective adipose tissues, including lipoaspirates, document MSC frequencies that are considerably higher than in BM aspirates (at least 2 orders of magnitude) (reviewed in [44]). In comparison, the abundance of MSCs in “yellow” fatty marrow aspirates observed in our study appears to be relatively minor (only a 2–5 fold higher than in classical “red” marrow aspirates). Given the unique function of adipocytes in the marrow [45–47] and the different metabolic functions of fat in different depot sites [47], our data indicate that the MSC pool size in “fatty tissues” is clearly site-specific. Variations in MSC function have been documented for different types of bone: orofacial, axial and appendicular [48] and different depots of fat: arm, flank, thigh and abdomen [49]. The heterogeneity of MSCs resident within seemingly the same type of tissues but located in different anatomical areas may be explained by varying local demands for tissue turnover and mechanical loads [48]. Additionally, the MSC topography in diverse human tissues has been described as primarily perivascular [50,51] and it is possible that the lower MSC frequency in fatty marrow as opposed to subcutaneous fat may be also related to blood vessel density as suggested previously for human synovium [52] and equine adipose tissue [53].

The fact that LBFMB-derived cultured MSCs were able to effectively differentiate towards osteoblasts and chondrocytes *in vitro* provided strong evidence that minimally expanded LBFMB-derived MSCs can be used as cell therapy for fracture non-unions. Furthermore, high numbers of CD45^{low}CD271⁺ cells present in LBFMB samples (up to 67,000, median 43,620 in 10 ml) suggested that their direct injection, in a one-stage procedure, may be possible without prior cell-culture. One previous study has showed that a dose of 50,000 uncultured MSCs from ~300 ml of ICBMA was efficacious following injection into non-union fracture sites [10]. A lower volume of LBFMB would therefore be sufficient to obtain a similar number of MSCs. Uncultured MSCs could be effectively concentrated using magnetic beads against the CD271 molecule, based on our findings showing that the proportions of CD45^{low}CD271⁺ cells closely reflected that of CFU-Fs [28].

The findings from this study also offer an additional cellular mechanism to explain the efficient bone healing process following LB fracture. They show, for the first time, that the marrow contents of long bones contain large numbers of functionally-competent local MSCs. Given a novel concept of local MSC recruitment to fracture sites [54,55] and our findings showing large numbers of MSCs in LBFMB in humans, our data point towards a potentially major contribution of locally-recruited LBFMB MSCs to healing of long bone fractures. Systemic MSC circulation in healthy humans and in response to injury remains poorly understood [56–60], and in this respect our findings showing no circulating MSCs in patients with fracture non-union (despite high MSC numbers in ICBM and LBFMB) are noteworthy. To the best of our knowledge, the enumeration and the ‘ex vivo’ phenotype of MSCs in LBFMB in comparison to donor-matched ICBMA have never been reported before. Furthermore, we showed that the marrow contents of long bones contained normal amounts of other cells with regenerative potential (CD34⁺ and CD31⁺ cells [61,62]) necessary to orchestrate the fracture healing processes.

In summary, this study demonstrates that the femoral IM cavity represents a depot of MSCs which could be used for autogenous/allogeneic use and can be harvested using ‘low-tech’ techniques for a variety of commonly performed operations including trauma surgery and total hip replacement. The IM cavities of long-bones, in which the FBM resides, are also readily accessible by the orthopaedic surgeon during lower-limb arthroplasty/nailing of long-bone fractures, with the marrow contents requiring removal prior to prosthesis insertion. Enumeration of MSCs from LBFMB is possible using the CD271⁺CD45^{low} phenotype and their concentration could be achieved with the use of magnetic beads against the CD271 molecule. The use of freshly-isolated or minimally-expanded LBFMB-derived MSCs could therefore have important scientific and economic benefits in tissue engineering and treatment of fracture non-unions.

Conflict of interest

The authors declare that there is no conflict of interest.

Acknowledgments

We gratefully acknowledge the help of Drs Sally Kinsey and Geoff Shenton for the collection of ICBMA from allogeneic bone marrow transplant donors. G.C. is supported by DePuy. S.A.B. is supported by PurStem—FP7 project No. 223298. S.C. is supported by NIHR-Leeds Musculoskeletal and Biomedical Research Unit (LMBRU). P.V.G. is part supported by the NIHR/LMBRU. CTB was supported by Science Foundation Ireland under the Short Term Travel Fellowship scheme (08/Y15/B1336 STTF 08). TR is supported by Kuwaiti government. This work was partially funded through WELMEC, a Centre of Excellence in Medical Engineering funded by the Wellcome Trust and EPSRC, under grant number WT 088908/Z/09/Z.

References

- [1] Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, et al. Multilineage potential of adult human mesenchymal stem cells. *Science* 1999;284:143–7.
- [2] Tuan RS, Boland G, Tuli R. Adult mesenchymal stem cells and cell-based tissue engineering. *Arthritis Res Ther* 2003;5:32–45.
- [3] Jones EA, Yang XB. Mesenchymal stem cells and their future in bone repair. *Int J Adv Rheumatol* 2005;3:15–21.
- [4] Lee EH, Hui JHP. The potential of stem cells in orthopaedic surgery. *J Bone Joint Surg Br* 2006;88-B:841–51.
- [5] Banfi A, Muraglia A, Dozin B, Mastrogiacomo M, Cancedda R, Quarto R. Proliferation kinetics and differentiation potential of *ex vivo* expanded human bone marrow stromal cells: implications for their use in cell therapy. *Exp Hematol* 2000;28:707–15.
- [6] DiGirolamo CM, Stokes D, Colter D, Phinney DG, Class R, Prockop DJ. Propagation and senescence of human marrow stromal cells in culture: a simple colony-forming assay identifies samples with the greatest potential to propagate and differentiate. *Br J Haematol* 1999;107:275–81.
- [7] Wagner W, Horn P, Castoldi M, Diehlmann A, Bork S, Saffrich R, et al. Replicative senescence of mesenchymal stem cells: a continuous and organized process. *PLoS One* 2008;3:e2213.
- [8] Miura M, Miura Y, Padilla-Nash HM, Molinolo AA, Fu BJ, Patel V, et al. Accumulated chromosomal instability in murine bone marrow mesenchymal stem cells leads to malignant transformation. *Stem Cells* 2006;24:1095–103.
- [9] Tarte K, Gaillard J, Lataillade JJ, Fouillard L, Becker M, Mossafa H, et al. Clinical-grade production of human mesenchymal stromal cells: occurrence of aneuploidy without transformation. *Blood* 2010;115:1549–53.
- [10] Hernigou P, Poignard A, Beaujean F, Rouard H. Percutaneous autologous bone-marrow grafting for nonunions — influence of the number and concentration of progenitor cells. *J Bone Joint Surg Am* 2005;87A:1430–7.
- [11] Mizuno H. Adipose-derived stem cells for tissue repair and regeneration: ten years of research and a literature review. *J Nippon Med Sch* 2009;76:56–66.
- [12] Im GI, Shin YW, Lee KB. Do adipose tissue-derived mesenchymal stem cells have the same osteogenic and chondrogenic potential as bone marrow-derived cells? *Osteoarthritis Cartilage* 2005;13:845–53.
- [13] Lin L, Shen Q, Wei XL, Hou Y, Xue T, Fu X, et al. Comparison of osteogenic potentials of BMP4 transduced stem cells from autologous bone marrow and fat tissue in a rabbit model of calvarial defects. *Calcif Tissue Int* 2009;85:55–65.
- [14] Hattori H, Masuoka K, Sato M, Ishihara M, Asazuma T, Takase B, et al. Bone formation using human adipose tissue-derived stromal cells and a biodegradable scaffold. *J Biomed Mater Res B Appl Biomater* 2006;76B:230–9.
- [15] Hattori H, Sato M, Masuoka K, Ishihara M, Kikuchi T, Matsui T, et al. Osteogenic potential of human adipose tissue-derived stromal cells as an alternative stem cell source. *Cells Tissues Organs* 2004;178:2–12.
- [16] Levi B, James AW, Nelson ER, Vistnes D, Wu B, Lee M, et al. Human adipose derived stromal cells heal critical size mouse calvarial defects. *PLoS One* 2010;5.
- [17] Seong JM, Kim BC, Park JH, Kwon IK, Mantalaris A, Hwang YS. Stem cells in bone tissue engineering. *Biomed Mater* 2010;5.
- [18] Nelea V, Luo L, Demers CN, Antoniou J, Petit A, Lerouge S, et al. Selective inhibition of type X collagen expression in human mesenchymal stem cell differentiation on polymer substrates surface-modified by glow discharge plasma. *J Biomed Mater Res A* 2005;75A:216–23.
- [19] Stolzing A, Scutt A. Age-related impairment of mesenchymal progenitor cell function. *Aging Cell* 2006;5:213–24.
- [20] Tropel P, Noel D, Platet N, Legrand P, Benabid AL, Berger F. Isolation and characterisation of mesenchymal stem cells from adult mouse bone marrow. *Exp Cell Res* 2004;295:395–406.
- [21] Huibregtse BA, Johnstone B, Goldberg VM, Caplan AI. Effect of age and sampling site on the chondro-osteogenic potential of rabbit marrow-derived mesenchymal progenitor cells. *J Orthop Res* 2000;18:18–24.
- [22] Im GI, Kim DY, Shin JH, Hyun CW, Cho WH. Repair of cartilage defect in the rabbit with cultured mesenchymal stem cells from bone marrow. *J Bone Joint Surg Br* 2001;83B:289–94.
- [23] Bennett JH, Joyner CJ, Triffitt JT, Owen ME. Adipocytic cells cultured from marrow have osteogenic potential. *J Cell Sci* 1991;99(Pt 1):131–9.
- [24] Meyer EG, Buckley CT, Thorpe SD, Kelly DJ. Low oxygen tension is a more potent promoter of chondrogenic differentiation than dynamic compression. *J Biomech* 2010;43:2516–23.
- [25] Thorpe SD, Buckley CT, Vinardell T, O'Brien FJ, Campbell VA, Kelly DJ. The response of bone marrow-derived mesenchymal stem cells to dynamic compression following TGF-beta 3 induced chondrogenic differentiation. *Ann Biomed Eng* 2010;38:2896–909.
- [26] Galotto M, Berisso G, Delfino L, Podesta M, Ottaggio L, Dallorso S, et al. Stromal damage as consequence of high-dose chemo/radiotherapy in bone marrow transplant recipients. *Exp Hematol* 1999;27:1460–6.
- [27] Jones EA, Kinsey SE, English A, Jones RA, Straszynski L, Meredith DM, et al. Isolation and characterization of bone marrow multipotential mesenchymal progenitor cells. *Arthritis Rheum* 2002;46:3349–60.
- [28] Jones EA, English A, Kinsey SE, Straszynski L, Emery P, Ponchel F, et al. Optimization of a flow cytometry-based protocol for detection and phenotypic characterization of multipotent mesenchymal stromal cells from human bone marrow. *Cytometry B Clin Cytom* 2006;70:391–9.
- [29] Buhning H-J, Battula VL, Trembl S, Schewe B, Kanz L, Vogel W. Novel markers for the prospective isolation of human MSC. *Ann N Y Acad Sci* 2007;1106:262–71.
- [30] Giannoudis PV, Tzioupis C, Green J. Surgical techniques: how I do it? The Reamer/Irrigator/Aspirator (RIA) System. *Inj Int J Care Inj* 2009;40:1231–6.
- [31] Castro-Malaspina H, Gay RE, Resnick G, Kapoor N, Maeyers P, Chiarieri D, et al. Characterisation of human bone marrow fibroblast colony-forming cells (CFU-F) and their progeny. *Blood* 1980;56:289–301.
- [32] Jones EA, English A, Henshaw K, Kinsey SE, Markham AF, Emery P, et al. Enumeration and phenotypic characterization of synovial fluid multipotential mesenchymal progenitor cells in inflammatory and degenerative arthritis. *Arthritis Rheum* 2004;50:817–27.
- [33] Jones E, Crawford A, English A, Henshaw K, Mundy J, Corscadden D, et al. Synovial fluid mesenchymal stem cells in health and early osteoarthritis: detection and functional evaluation at the single-cell level. *Arthritis Rheum* 2008;58:1731–40.
- [34] Buckley CT, Vinardell T, Thorpe SD, Haugh MG, Jones E, McGonagle D, et al. Functional properties of cartilaginous tissues engineered from infrapatellar fat pad-derived mesenchymal stem cells. *J Biomech* 2010;43:920–6.
- [35] Jones E, English A, Churchman SM, Kouroupis D, Boxall SA, Kinsey S, et al. Large-scale extraction and characterization of CD271⁺ multipotential stromal cells from trabecular bone in health and osteoarthritis: implications for bone regeneration strategies based on uncultured or minimally cultured multipotential stromal cells. *Arthritis Rheum* 2010;62:1944–54.
- [36] Battula VL, Trembl S, Bareiss PM, Gieseke F, Roelofs H, de Zwart P, et al. Isolation of functionally distinct mesenchymal stem cell subsets using antibodies against CD56, CD271, and mesenchymal stem cell antigen-1. *Haematologica* 2009;94:173–84.
- [37] Kuci S, Kuci Z, Kreyenberg H, Deak E, Putsch K, Huenecke S, et al. CD271 antigen defines a subset of multipotent stromal cells with immunosuppressive and lymphohematopoietic engraftment-promoting properties. *Haematologica* 2010;95:651–9.
- [38] D'Ippolito G, Schiller PC, Ricordi C, Roos BA, Howard GA. Age-related osteogenic potential of mesenchymal stromal stem cells from human vertebral bone marrow. *J Bone Miner Res* 1999;14:1115–22.
- [39] Veyrat-Masson R, Boiret-Dupre N, Rapatel C, Descamps S, Guilloard L, Guerin J-J, et al. Mesenchymal content of fresh bone marrow: a proposed quality control method for cell therapy. *Br J Haematol* 2007;139:312–20.
- [40] Kim H, Cho HJ, Kim SW, Liu BL, Choi YJ, Lee J, et al. CD31(+) Cells represent highly angiogenic and vasculogenic cells in bone marrow novel role of nonendothelial CD31(+) cells in neovascularization and their therapeutic effects on ischemic vascular disease. *Circ Res* 2010;107:602–14.
- [41] Quirici N, Scavullo C, de Girolamo L, Lopa S, Arrighi E, Delilieri GL, et al. Anti-L-NGFR and-CD34 monoclonal antibodies identify multipotent mesenchymal stem cells in human adipose tissue. *Stem Cells* 2010;19:915–25.
- [42] Emery JL, Follett GF. Regression of bone-marrow haemopoiesis from terminal digits in foetus + infant. *Br J Haematol* 1964;10:485–9.
- [43] Piney A. The anatomy of the bone marrow: with special reference to the distribution of the red marrow. *Br Med J* 1922;1922:792–5.
- [44] Fraser JK, Wulur I, Alfonso Z, Hedrick MH. Fat tissue: an underappreciated source of stem cells for biotechnology. *Trends Biotechnol* 2006;24:150–4.
- [45] Gimble JM, Robinson CE, Wu X, Kelly KA. The function of adipocytes in the bone marrow stroma: an update. *Bone* 1996;19:421–8.
- [46] Corre J, Planat-Benard V, Corberand JX, Penicaud L, Casteilla L, Laharrague P. Human bone marrow adipocytes support complete myeloid and lymphoid differentiation from human CD34(+) cells. *Br J Haematol* 2004;127:344–7.
- [47] Rosen CJ, Ackert-Bicknell C, Rodriguez JP, Pino AM. Marrow fat and the bone microenvironment: developmental, functional, and pathological implications. *Crit Rev Eukaryot Gene Expr* 2009;19:109–24.
- [48] Akintoye SO, Lam T, Shi ST, Ibrahim J, Collins MT, Robey PG. Skeletal site-specific characterization of orofacial and iliac crest human bone marrow stromal cells in same individuals. *Bone* 2006;38:758–68.
- [49] Levi B, James AW, Glotzbach JP, Wan DC, Commons GW, Longaker MT. Depot-specific variation in the osteogenic and adipogenic potential of human adipose-derived stromal cells. *Plastic Reconstr Surg* 2010;126:822–34.
- [50] Meirelles LD, Caplan AI, Nardi NB. In search of the *in vivo* identity of mesenchymal stem cells. *Stem Cells* 2008;26:2287–99.

- [51] Crisan M, Yap S, Casteilla L, Chen CW, Corselli M, Park TS, et al. A perivascular origin for mesenchymal stem cells in multiple human organs. *Cell Stem Cell* 2008;3:301–13.
- [52] Nagase T, Muneta T, Ju YJ, Hara K, Morito T, Koga H, et al. Analysis of the chondrogenic potential of human synovial stem cells according to harvest site and culture parameters in knees with medial compartment osteoarthritis. *Arthritis Rheum* 2008;58:1389–98.
- [53] Meirelles LD, Sand TT, Harman RJ, Lennon DP, Caplan AL. MSC frequency correlates with blood vessel density in equine adipose tissue. *Tissue Eng Part A* 2009;15:221–9.
- [54] Ito H. Chemokines in mesenchymal stem cell therapy for bone repair: a novel concept of recruiting mesenchymal stem cells and the possible cell sources. *Mod Rheumatol* 2011;21:113–21.
- [55] Kitaori T, Ito H, Schwarz EA, Tsutsumi R, Yoshitomi H, Oishi S, et al. Stromal cell-derived factor 1/CXCR4 Signaling is critical for the recruitment of mesenchymal stem cells to the fracture site during skeletal repair in a mouse model. *Arthritis Rheum* 2009;60:813–23.
- [56] Kuznetsov SA, Mankani MH, Gronthos S, Satomura K, Bianco P, Robey PG. Circulating skeletal stem cells. *J Cell Biol* 2001;153:1133–9.
- [57] Jones E, McGonagle D. Human bone marrow mesenchymal stem cells in vivo. *Rheumatology* 2008;47:126–31.
- [58] Mansilla E, Marin GH, Drago H, Sturla F, Salas E, Gardiner C, et al. Bloodstream cells phenotypically identical to human mesenchymal bone marrow stem cells circulate in large amounts under the influence of acute large skin damage: new evidence for their use in regenerative medicine. *Transplant Proc* 2006;38:967–9.
- [59] Khosla S, Eghbali-Fatourehchi GZ. Circulating cells with osteogenic potential. *Ann N Y Acad Sci* 2006;1068:489–97.
- [60] Marsell R, Einhorn TA. The biology of fracture healing. *Injury* 2011;42:551–5.
- [61] Matsumoto T, Kawamoto A, Kuroda R, Ishikawa M, Mifune Y, Iwasaki H, et al. Therapeutic potential of vasculogenesis and osteogenesis promoted by peripheral blood CD34-positive cells for functional bone healing. *Am J Pathol* 2006;169:1440–57.
- [62] Yu HY, VandeVord PJ, Mao L, Matthew HW, Wooley PH, Yang SY. Improved tissue-engineered bone regeneration by endothelial cell mediated vascularization. *Biomaterials* 2009;30:508–17.